{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:29:35Z","timestamp":1779935375808,"version":"3.53.1"},"reference-count":164,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100013262","name":"State Key Laboratory of Respiratory Disease","doi-asserted-by":"publisher","award":["SKLRD-OP-202317"],"award-info":[{"award-number":["SKLRD-OP-202317"]}],"id":[{"id":"10.13039\/100013262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Guangdong Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2022A1515012408"],"award-info":[{"award-number":["2022A1515012408"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013125"],"award-info":[{"award-number":["2024A1515013125"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272326"],"award-info":[{"award-number":["82272326"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32460899"],"award-info":[{"award-number":["32460899"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009659","name":"Guangzhou Medical University","doi-asserted-by":"publisher","award":["JCXKJS2022A11"],"award-info":[{"award-number":["JCXKJS2022A11"]}],"id":[{"id":"10.13039\/100009659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ijbiomac.2025.146204","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T05:49:10Z","timestamp":1753076950000},"page":"146204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P1","title":["mRNA vaccines: Emerging opportunities for herpesvirus prevention and therapeutic intervention"],"prefix":"10.1016","volume":"321","author":[{"given":"Wenjie","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsheng","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingsong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinghong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0005","doi-asserted-by":"crossref","DOI":"10.1099\/jgv.0.001673","article-title":"Ictv virus taxonomy profile: Herpesviridae 2021","volume":"102","author":"Gatherer","year":"2021","journal-title":"J. Gen. Virol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/v14071379","article-title":"The role of latency-associated transcripts in the latent infection of pseudorabies virus","volume":"14","author":"Deng","year":"2022","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0015","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.idc.2023.02.011","article-title":"Genital herpes infection: Progress and problems","volume":"37","author":"Van Wagoner","year":"2023","journal-title":"Infect. Dis. Clin. N. Am."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0020","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1172\/JCI136225","article-title":"Herpesvirus latency","volume":"130","author":"Cohen","year":"2020","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0025","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/jcm13020640","article-title":"Cytomegalovirus and pregnancy: a narrative review","volume":"13","author":"Pontes","year":"2024","journal-title":"J. Clin. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0030","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41579-021-00582-z","article-title":"Pathogenesis of human cytomegalovirus in the immunocompromised host","volume":"19","author":"Griffiths","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.146204_bb0035","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","article-title":"Epstein-barr virus: biology and clinical disease","volume":"185","author":"Damania","year":"2022","journal-title":"Cell"},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.146204_bb0040","doi-asserted-by":"crossref","first-page":"7631","DOI":"10.1111\/febs.16206","article-title":"Cancers associated with human gammaherpesviruses","volume":"289","author":"Wen","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0045","series-title":"Fields\u2019 virology","author":"Fields","year":"2007"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0050","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s00277-021-04746-y","volume":"101","author":"Henze","year":"2022","journal-title":"Ann. Hematol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0055","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1007\/s40588-023-00202-9","article-title":"Intimate relationship between stress and human alpha-herpes virus 1 (hsv-1) reactivation from latency","volume":"10","author":"Jones","year":"2023","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0060","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/all.14587","article-title":"Pollen induces reactivation of latent herpesvirus and differentially affects infected and uninfected murine macrophages","volume":"76","author":"Speidel","year":"2021","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0065","doi-asserted-by":"crossref","DOI":"10.1111\/petr.14819","article-title":"Varicella-zoster virus reactivation after pediatric allogeneic hematopoietic stem cell transplantation, single-center experience of acyclovir prophylaxis","volume":"28","author":"Ar\u0131c\u0131","year":"2024","journal-title":"Pediatr. Transplant."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15122721","article-title":"30-year development of inactivated virus vaccine in China","volume":"15","author":"Shi","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0075","doi-asserted-by":"crossref","DOI":"10.3390\/toxins15090563","article-title":"Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines","volume":"15","author":"Gupta","year":"2023","journal-title":"Toxins (Basel)"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.146204_bb0080","doi-asserted-by":"crossref","DOI":"10.1111\/1751-7915.70053","article-title":"New insights for the development of efficient DNA vaccines","volume":"17","author":"Berger","year":"2024","journal-title":"Microb. Biotechnol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0085","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1038\/s41591-023-02517-y","article-title":"Original sars-cov-2 monovalent and omicron Ba.4\/Ba.5 bivalent covid-19 mrna vaccines: phase 2\/3 trial interim results","volume":"29","author":"Chalkias","year":"2023","journal-title":"Nat. Med."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0090","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of covid-19 with the bnt162b2 and mrna-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923647","article-title":"Potentialities and challenges of mrna vaccine in cancer immunotherapy","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41392-022-00950-y","article-title":"Advances in covid-19 mrna vaccine development","volume":"7","author":"Fang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0105","doi-asserted-by":"crossref","first-page":"5357","DOI":"10.1007\/s12274-022-5254-x","article-title":"A lipid-based lmp2-mrna vaccine to treat nasopharyngeal carcinoma","volume":"16","author":"Guo","year":"2023","journal-title":"Nano Res"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0110","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3390\/v14020296","article-title":"Well put together-a guide to accessorizing with the herpesvirus GH\/GL complexes","volume":"14","author":"Del Gonzalez- Pino","year":"2022","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0115","doi-asserted-by":"crossref","first-page":"800","DOI":"10.3390\/v4050800","article-title":"Herpes virus fusion and entry: a story with many characters","volume":"4","author":"Eisenberg","year":"2012","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0120","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.1128\/JVI.72.7.6119-6130.1998","article-title":"Heparan sulfate proteoglycan binding by herpes simplex virus type 1 glycoproteins b and c, which differ in their contributions to virus attachment, penetration, and cell-to-cell spread","volume":"72","author":"Laquerre","year":"1998","journal-title":"J. Virol."},{"issue":"Pt 10","key":"10.1016\/j.ijbiomac.2025.146204_bb0125","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1099\/vir.0.2008\/003129-0","article-title":"Dendritic cells mediate herpes simplex virus infection and transmission through the c-type lectin DC-SIGN","volume":"89","author":"de Jong","year":"2008","journal-title":"J. Gen. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0130","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2005.09.016","article-title":"Different receptors binding to distinct interfaces on herpes simplex virus gd can trigger events leading to cell fusion and viral entry","volume":"344","author":"Spear","year":"2006","journal-title":"Virology"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006314","article-title":"Structural basis of nectin-1 recognition by pseudorabies virus glycoprotein d","volume":"13","author":"Li","year":"2017","journal-title":"PLoS Pathog."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0140","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s40588-016-0044-4","article-title":"Varicella-zoster virus glycoproteins: entry, replication, and pathogenesis","volume":"3","author":"Oliver","year":"2016","journal-title":"Curr. Clin. Microbiol. Rep."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.146204_bb0145","doi-asserted-by":"crossref","first-page":"7567","DOI":"10.1128\/JVI.00792-16","article-title":"Role for the \u03b1v integrin subunit in varicella-zoster virus-mediated fusion and infection","volume":"90","author":"Yang","year":"2016","journal-title":"J. Virol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0150","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.02625-21","article-title":"Cryo-electron microscopy structure and interactions of the human cytomegalovirus ghglgo trimer with platelet-derived growth factor receptor alpha","volume":"12","author":"Liu","year":"2021","journal-title":"mBio"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0155","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abm2546","article-title":"Structural basis for hcmv pentamer recognition by neuropilin 2 and neutralizing antibodies","volume":"8","author":"Wrapp","year":"2022","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0160","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/1348-0421.12110","article-title":"Human herpesvirus-6a gq1 and gq2 are critical for human cd46 usage","volume":"58","author":"Jasirwan","year":"2014","journal-title":"Microbiol. Immunol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0165","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008648","article-title":"Structural basis for the interaction of human herpesvirus 6b tetrameric glycoprotein complex with the cellular receptor, human cd134","volume":"16","author":"Nishimura","year":"2020","journal-title":"PLoS Pathog."},{"issue":"19","key":"10.1016\/j.ijbiomac.2025.146204_bb0170","doi-asserted-by":"crossref","first-page":"10900","DOI":"10.1128\/JVI.01427-13","article-title":"Herpesvirus 6 glycoproteins b (gb), gh, gl, and gq are necessary and sufficient for cell-to-cell fusion","volume":"87","author":"Tanaka","year":"2013","journal-title":"J. Virol."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.146204_bb0175","doi-asserted-by":"crossref","first-page":"e00311","DOI":"10.1128\/JVI.00311-20","article-title":"Gp96 is critical for both human herpesvirus 6a (hhv-6a) and hhv-6b infections","volume":"94","author":"Ma","year":"2020","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0180","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1128\/JVI.78.9.4609-4616.2004","article-title":"Discovery of a second form of tripartite complex containing gh-gl of human herpesvirus 6 and observations on cd46","volume":"78","author":"Mori","year":"2004","journal-title":"J. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0185","doi-asserted-by":"crossref","first-page":"4571","DOI":"10.1128\/jvi.71.6.4571-4580.1997","article-title":"Role of the extracellular domain of human herpesvirus 7 glycoprotein b in virus binding to cell surface heparan sulfate proteoglycans","volume":"71","author":"Secchiero","year":"1997","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0190","doi-asserted-by":"crossref","first-page":"4530","DOI":"10.1128\/JVI.74.10.4530-4540.2000","article-title":"Identification and analysis of a novel heparin-binding glycoprotein encoded by human herpesvirus 7","volume":"74","author":"Skrincosky","year":"2000","journal-title":"J. Virol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0195","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1073\/pnas.91.9.3872","article-title":"Cd4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus","volume":"91","author":"Lusso","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0200","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/nrmicro2548","article-title":"Fusing structure and function: a structural view of the herpesvirus entry machinery","volume":"9","author":"Connolly","year":"2011","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.jmgm.2022.108196","article-title":"How epstein-barr virus envelope glycoprotein gp350 tricks the cr2? A molecular dynamics study","volume":"114","author":"Bing\u00f6l","year":"2022","journal-title":"J. Mol. Graph. Model."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0210","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.immuni.2024.02.008","article-title":"Epstein-barr virus gp42 antibodies reveal sites of vulnerability for receptor binding and fusion to b cells","volume":"57","author":"Bu","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0215","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.virol.2007.09.012","article-title":"The epstein-barr virus bmrf-2 protein facilitates virus attachment to oral epithelial cells","volume":"370","author":"Xiao","year":"2008","journal-title":"Virology"},{"issue":"48","key":"10.1016\/j.ijbiomac.2025.146204_bb0220","doi-asserted-by":"crossref","first-page":"20464","DOI":"10.1073\/pnas.0907508106","article-title":"Fusion of epithelial cells by epstein-barr virus proteins is triggered by binding of viral glycoproteins ghgl to integrins alphavbeta6 or alphavbeta8","volume":"106","author":"Chesnokova","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"24","key":"10.1016\/j.ijbiomac.2025.146204_bb0225","doi-asserted-by":"crossref","first-page":"13214","DOI":"10.1128\/JVI.05580-11","article-title":"Fusion of epstein-barr virus with epithelial cells can be triggered by \u03b1v\u03b25 in addition to \u03b1v\u03b26 and \u03b1v\u03b28, and integrin binding triggers a conformational change in glycoproteins ghgl","volume":"85","author":"Chesnokova","year":"2011","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0230","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/s41564-017-0081-7","article-title":"Ephrin receptor a2 is a functional entry receptor for epstein\u2013barr virus","volume":"3","author":"Chen","year":"2018","journal-title":"Nat. Microbiol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.146204_bb0235","doi-asserted-by":"crossref","first-page":"7517","DOI":"10.1128\/JVI.75.16.7517-7527.2001","article-title":"Human herpesvirus 8 envelope glycoprotein k8.1a interaction with the target cells involves heparan sulfate","volume":"75","author":"Wang","year":"2001","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0240","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1006\/viro.2001.0921","article-title":"Human herpesvirus 8 envelope-associated glycoprotein b interacts with heparan sulfate-like moieties","volume":"284","author":"Akula","year":"2001","journal-title":"Virology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/v13010118","article-title":"Cellular receptors involved in KSHV infection","volume":"13","author":"van der Meulen","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1128\/jvi.14.1.8-19.1974","article-title":"Regulation of herpesvirus macromolecular synthesis. I. Cascade regulation of the synthesis of three groups of viral proteins","volume":"14","author":"Honess","year":"1974","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0255","doi-asserted-by":"crossref","first-page":"110653","DOI":"10.1016\/j.celrep.2022.110653","article-title":"Temporal dynamics of hcmv gene expression in lytic and latent infections","volume":"39","author":"Rozman","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110324","article-title":"Mechanisms of hsv gene regulation during latency and reactivation","volume":"602","author":"Fu","year":"2025","journal-title":"Virology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0265","doi-asserted-by":"crossref","DOI":"10.3390\/v14061215","article-title":"Microrna regulation of human herpesvirus latency","volume":"14","author":"Chen","year":"2022","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0270","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1038\/s41467-018-03569-2","article-title":"A spliced latency-associated vzv transcript maps antisense to the viral transactivator gene 61","volume":"9","author":"Depledge","year":"2018","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0275","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens9020125","article-title":"Herpesviral latency-common themes","volume":"9","author":"Weidner-Glunde","year":"2020","journal-title":"Pathogens"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0280","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01754-17","article-title":"Latency-associated expression of human cytomegalovirus us28 attenuates cell signaling pathways to maintain latent infection","volume":"8","author":"Krishna","year":"2017","journal-title":"mBio"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0285","doi-asserted-by":"crossref","DOI":"10.3390\/cells9122608","article-title":"The u94 gene of human herpesvirus 6: a narrative review of its role and potential functions","volume":"9","author":"Caselli","year":"2020","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0290","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1128\/JVI.02007-14","article-title":"A human herpesvirus 6a-encoded microrna: role in viral lytic replication","volume":"89","author":"Nukui","year":"2015","journal-title":"J. Virol."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.146204_bb0295","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1128\/JVI.76.8.4145-4151.2002","article-title":"Identification of human herpesvirus 6 latency-associated transcripts","volume":"76","author":"Kondo","year":"2002","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0300","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1128\/JVI.77.3.2258-2264.2003","article-title":"Recognition of a novel stage of betaherpesvirus latency in human herpesvirus 6","volume":"77","author":"Kondo","year":"2003","journal-title":"J. Virol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0305","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.3390\/v13122344","article-title":"Molecular basis of epstein-barr virus latency establishment and lytic reactivation","volume":"13","author":"Murata","year":"2021","journal-title":"Viruses"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.146204_bb0310","doi-asserted-by":"crossref","first-page":"9027","DOI":"10.1128\/JVI.00721-14","article-title":"Microrna mir-bart20-5p stabilizes epstein-barr virus latency by directly targeting bzlf1 and brlf1","volume":"88","author":"Jung","year":"2014","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0315","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01268-23","article-title":"Kaposi's sarcoma-associated herpesvirus (kshv) lana prevents kshv episomes from degradation","volume":"98","author":"Nakajima","year":"2024","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2016.00054","article-title":"Kshv genome replication and maintenance","volume":"7","author":"Purushothaman","year":"2016","journal-title":"Front. Microbiol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0325","doi-asserted-by":"crossref","first-page":"e02410","DOI":"10.1128\/mBio.02410-20","article-title":"Human cytomegalovirus genomes survive mitosis via the ie19 chromatin-tethering domain","volume":"11","author":"Lyon","year":"2020","journal-title":"mBio"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0330","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.tim.2019.09.002","article-title":"Control of viral latency by episome maintenance proteins","volume":"28","author":"De Leo","year":"2020","journal-title":"Trends Microbiol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0335","doi-asserted-by":"crossref","first-page":"4961","DOI":"10.3390\/v6124961","article-title":"KSHV lana--the master regulator of KSHV latency","volume":"6","author":"Uppal","year":"2014","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104720","article-title":"Current understanding of human herpesvirus 6 (hhv-6) chromosomal integration","volume":"176","author":"Aimola","year":"2020","journal-title":"Antivir. Res."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0345","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1128\/JVI.72.3.2010-2021.1998","article-title":"The genome sequence of herpes simplex virus type 2","volume":"72","author":"Dolan","year":"1998","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0350","doi-asserted-by":"crossref","DOI":"10.3390\/v15010225","article-title":"A comprehensive overview of epidemiology, pathogenesis and the management of herpes labialis","volume":"15","author":"Gopinath","year":"2023","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.146204_bb0355","doi-asserted-by":"crossref","DOI":"10.1172\/JCI164317","article-title":"Hsv-2 triggers upregulation of malat1 in cd4+ t cells and promotes hiv latency reversal","volume":"133","author":"Pierce","year":"2023","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.146204_bb0360","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29024","article-title":"Neonatal herpes simplex virus infection: from the maternal infection to the child outcome","volume":"95","author":"De Rose","year":"2023","journal-title":"J. Med. Virol."},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0365","article-title":"Clinical management of herpes simplex virus keratitis","volume":"12","author":"Labib","year":"2022","journal-title":"Diagnostics (Basel)"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0370","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s40475-022-00255-8","article-title":"Herpesvirus-associated encephalitis: An update","volume":"9","author":"Matthews","year":"2022","journal-title":"Curr. Trop. Med. Rep."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0375","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s43556-024-00199-7","article-title":"A review of hsv pathogenesis, vaccine development, and advanced applications","volume":"5","author":"Bai","year":"2024","journal-title":"Mol. Biomed."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0380","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/infdis\/jiz225","article-title":"A randomized, double-blinded, placebo-controlled, phase 1 study of a replication-defective herpes simplex virus (hsv) type 2 vaccine, hsv529, in adults with or without hsv infection","volume":"220","author":"Dropulic","year":"2019","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0385","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa1103151","article-title":"Efficacy results of a trial of a herpes simplex vaccine","volume":"366","author":"Belshe","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0390","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006141","article-title":"An hsv-2 trivalent vaccine is immunogenic in rhesus macaques and highly efficacious in guinea pigs","volume":"13","author":"Awasthi","year":"2017","journal-title":"PLoS Pathog."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0395","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3390\/vaccines13050497","article-title":"A qs21 + cpg-adjuvanted trivalent hsv-2 vaccine and trivalent hsv-2 mrna vaccine induce a strong immune response, protect against hsv-2 infection, and cross-protect against hsv-1 infection in mice","volume":"13","author":"Cao","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"39","key":"10.1016\/j.ijbiomac.2025.146204_bb0400","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aaw7083","article-title":"Nucleoside-modified mRNA encoding HSV-2 glycoproteins c, d, and e prevents clinical and subclinical genital herpes","volume":"4","author":"Awasthi","year":"2019","journal-title":"Sci. Immunol."},{"issue":"47","key":"10.1016\/j.ijbiomac.2025.146204_bb0405","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1016\/j.vaccine.2020.09.079","article-title":"Protection against herpes simplex virus type 2 infection in a neonatal murine model using a trivalent nucleoside-modified mRNA in lipid nanoparticle vaccine","volume":"38","author":"LaTourette","year":"2020","journal-title":"Vaccine"},{"issue":"23","key":"10.1016\/j.ijbiomac.2025.146204_bb0410","doi-asserted-by":"crossref","DOI":"10.1172\/JCI152310","article-title":"Trivalent nucleoside-modified mrna vaccine yields durable memory b cell protection against genital herpes in preclinical models","volume":"131","author":"Awasthi","year":"2021","journal-title":"J. Clin. Invest."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1008795","article-title":"An hsv-2 nucleoside-modified mrna genital herpes vaccine containing glycoproteins gc, gd, and ge protects mice against hsv-1 genital lesions and latent infection","volume":"16","author":"Egan","year":"2020","journal-title":"PLoS Pathog."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0420","doi-asserted-by":"crossref","DOI":"10.3390\/v15071483","article-title":"A trivalent HSV-2 gC2, gD2, gE2 nucleoside-modified mRNA-LNP vaccine provides outstanding protection in mice against genital and non-genital HSV-1 infection, comparable to the same antigens derived from HSV-1","volume":"15","author":"Egan","year":"2023","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0425","doi-asserted-by":"crossref","DOI":"10.3390\/v14020192","article-title":"Herpes zoster: a review of clinical manifestations and management","volume":"14","author":"Patil","year":"2022","journal-title":"Viruses"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/v13030485","article-title":"Varicella-zoster virus infection of neurons derived from neural stem cells","volume":"13","author":"Kennedy","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0435","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/s41541-023-00757-0","article-title":"Healthy ageing: herpes zoster infection and the role of zoster vaccination","volume":"8","author":"Curran","year":"2023","journal-title":"NPJ Vaccines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0440","article-title":"Structures of the varicella zoster virus glycoprotein e and epitope mapping of vaccine-elicited antibodies","volume":"12","author":"Harshbarger","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0011327","article-title":"Insulin degrading enzyme induces a conformational change in varicella-zoster virus ge, and enhances virus infectivity and stability","volume":"5","author":"Li","year":"2010","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.ijbiomac.2025.146204_bb0450","doi-asserted-by":"crossref","first-page":"8525","DOI":"10.1128\/JVI.00286-07","article-title":"The amino terminus of varicella-zoster virus (vzv) glycoprotein e is required for binding to insulin-degrading enzyme, a vzv receptor","volume":"81","author":"Li","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0455","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076321","article-title":"Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records","volume":"383","author":"Klein","year":"2023","journal-title":"Bmj"},{"issue":"22","key":"10.1016\/j.ijbiomac.2025.146204_bb0460","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1056\/NEJMoa1501184","article-title":"Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults","volume":"372","author":"Lal","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.146204_bb0465","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1080\/21645515.2020.1741312","article-title":"Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials","volume":"16","author":"Colindres","year":"2020","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0470","article-title":"Qs-21: a potent vaccine adjuvant","volume":"3","author":"Zhu","year":"2016","journal-title":"Nat. Prod. Chem. Res."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.146204_bb0475","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202310886","article-title":"A synergistic lipid nanoparticle encapsulating mrna shingles vaccine induces potent immune responses and protects guinea pigs from viral challenges","volume":"36","author":"Cheng","year":"2024","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0480","doi-asserted-by":"crossref","first-page":"8029","DOI":"10.2147\/IJN.S464720","article-title":"Heterologous prime-boost immunization strategies using varicella-zoster virus ge mrna vaccine and adjuvanted protein subunit vaccine triggered superior cell immune response in middle-aged mice","volume":"19","author":"Li","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0485","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/vaccines13010068","article-title":"Development and evaluation of the immunogenic potential of an unmodified nucleoside mrna vaccine for herpes zoster","volume":"13","author":"Zhang","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0490","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41541-025-01093-1","article-title":"A highly stable lyophilized mrna vaccine for herpes zoster provides potent cellular and humoral responses","volume":"10","author":"Munoz-Moreno","year":"2025","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0495","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2309985","article-title":"Herpes zoster mRNA vaccine induces superior vaccine immunity over licensed vaccine in mice and rhesus macaques","volume":"13","author":"Huang","year":"2024","journal-title":"Emerg. Microbes Infect."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0500","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41541-024-00865-5","article-title":"Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mrna-lnp vaccine","volume":"9","author":"Bhattacharya","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0505","article-title":"An mRNA vaccine for herpes zoster and its efficacy evaluation in na\u00efve\/primed murine models","volume":"13","author":"Jiang","year":"2025","journal-title":"Vaccines (Basel)"},{"issue":"36","key":"10.1016\/j.ijbiomac.2025.146204_bb0510","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.vaccine.2020.06.062","article-title":"Immunogenicity generated by mrna vaccine encoding vzv ge antigen is comparable to adjuvanted subunit vaccine and better than live attenuated vaccine in nonhuman primates","volume":"38","author":"Monslow","year":"2020","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0515","doi-asserted-by":"crossref","first-page":"2495607","DOI":"10.1080\/21645515.2025.2495607","article-title":"Varicella zoster virus mrna vaccine candidate induced superior cellular immunity and comparable humoral and fc-mediated immunity compared to the licensed subunit vaccine in a mouse model","volume":"21","author":"Jang","year":"2025","journal-title":"Hum. Vaccin. Immunother."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0520","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9121440","article-title":"Effects of varicella-zoster virus glycoprotein e carboxyl-terminal mutation on mRNA vaccine efficacy","volume":"9","author":"Cao","year":"2021","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0525","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11091475","article-title":"Evaluation of the immunological efficacy of an LNP-mRNA vaccine prepared from varicella zoster virus glycoprotein gE with a double-mutated carboxyl terminus in different untranslated regions in mice","volume":"11","author":"Wang","year":"2023","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0530","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1128\/JVI.78.1.424-440.2004","article-title":"Complete, annotated sequence of the pseudorabies virus genome","volume":"78","author":"Klupp","year":"2004","journal-title":"J. Virol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0535","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.3390\/v14071463","article-title":"The epidemiology and variation in pseudorabies virus: a continuing challenge to pigs and humans","volume":"14","author":"Liu","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0540","doi-asserted-by":"crossref","first-page":"1475400","DOI":"10.3389\/fvets.2024.1475400","article-title":"Intrauterine inoculation of pseudorabies virus impairs mouse embryo implantation via inducing inflammation and apoptosis in endometrium","volume":"11","author":"Chen","year":"2024","journal-title":"Front. Vet. Sci."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0545","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1007\/s10072-021-05633-0","article-title":"Human viral encephalitis associated with suid herpesvirus 1","volume":"43","author":"Zhou","year":"2022","journal-title":"Neurol. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0550","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2022.973450","article-title":"Pseudorabies in pig industry of China: epidemiology in pigs and practitioner awareness","volume":"9","author":"Tan","year":"2022","journal-title":"Front. Vet. Sci."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0555","doi-asserted-by":"crossref","DOI":"10.1016\/j.vetmic.2020.108886","article-title":"Immunogenicity and protective efficacy induced by an mrna vaccine encoding gd antigen against pseudorabies virus infection","volume":"251","author":"Jiang","year":"2020","journal-title":"Vet. Microbiol."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0560","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s11262-017-1454-y","article-title":"A live gi\/ge-deleted pseudorabies virus (prv) protects weaned piglets against lethal variant prv challenge","volume":"53","author":"Yin","year":"2017","journal-title":"Virus Genes"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0565","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.vaccine.2005.09.041","article-title":"A DNA vaccine coding for gb and gd of pseudorabies virus (suid herpes type 1) primes the immune system in the presence of maternal immunity more efficiently than conventional vaccines","volume":"24","author":"van Rooij","year":"2006","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.ijbiomac.2025.146204_bb0570","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms10101880","article-title":"The immune efficacy of inactivated pseudorabies vaccine prepared from fj-2012\u03b4ge\/gi strain","volume":"10","author":"Chen","year":"2022","journal-title":"Microorganisms"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0575","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12985-022-01748-8","article-title":"Construction of a quadruple gene-deleted vaccine confers complete protective immunity against emerging prv variant challenge in piglets","volume":"19","author":"Sun","year":"2022","journal-title":"Virol. J."},{"issue":"30","key":"10.1016\/j.ijbiomac.2025.146204_bb0580","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221797120","article-title":"Genomic and geographical structure of human cytomegalovirus","volume":"120","author":"Charles","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0585","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2034","article-title":"Estimation of the worldwide seroprevalence of cytomegalovirus: a systematic review and meta-analysis","volume":"29","author":"Zuhair","year":"2019","journal-title":"Rev. Med. Virol."},{"issue":"37","key":"10.1016\/j.ijbiomac.2025.146204_bb0590","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2404250121","article-title":"Structure-based design of a soluble human cytomegalovirus glycoprotein b antigen stabilized in a prefusion-like conformation","volume":"121","author":"Sponholtz","year":"2024","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0595","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12985-020-01320-2","article-title":"Comparative neutralizing potencies of antibodies suggest conservation as well as mechanistic differences in human cytomegalovirus entry into epithelial and endothelial cells","volume":"17","author":"Qi","year":"2020","journal-title":"Virol. J."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0600","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1086\/340637","article-title":"Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals","volume":"185","author":"Kern","year":"2002","journal-title":"J. Infect. Dis."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0605","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1084\/jem.168.3.919","article-title":"Human cytomegalovirus-specific cytotoxic t cells. Relative frequency of stage-specific ctl recognizing the 72-kd immediate early protein and glycoprotein b expressed by recombinant vaccinia viruses","volume":"168","author":"Borysiewicz","year":"1988","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0610","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1056\/NEJMoa0804749","article-title":"Vaccine prevention of maternal cytomegalovirus infection","volume":"360","author":"Pass","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0615","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1111\/ajt.14925","article-title":"A randomized, phase 2 study of asp0113, a DNA-based vaccine, for the prevention of cmv in cmv-seronegative kidney transplant recipients receiving a kidney from a cmv-seropositive donor","volume":"18","author":"Vincenti","year":"2018","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0620","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/S1473-3099(23)00343-2","article-title":"Safety, efficacy, and immunogenicity of a replication-defective human cytomegalovirus vaccine, v160, in cytomegalovirus-seronegative women: a double-blind, randomised, placebo-controlled, phase 2b trial","volume":"23","author":"Das","year":"2023","journal-title":"Lancet Infect. Dis."},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0625","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00186-20","article-title":"Human cytomegalovirus glycoprotein b nucleoside-modified mRNA vaccine elicits antibody responses with greater durability and breadth than MF59-adjuvanted gb protein immunization","volume":"94","author":"Nelson","year":"2020","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0630","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/S0923-2516(98)80086-1","article-title":"A fifth human cytomegalovirus glycoprotein b genotype","volume":"149","author":"Shepp","year":"1998","journal-title":"Res. Virol."},{"issue":"7","key":"10.1016\/j.ijbiomac.2025.146204_bb0635","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24076304","article-title":"Cytomegalovirus glycoprotein b genotype in patients with anterior segment infection","volume":"24","author":"Huang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/v13061106","article-title":"Common polymorphisms in the glycoproteins of human cytomegalovirus and associated strain-specific immunity","volume":"13","author":"Wang","year":"2021","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0645","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41541-024-00821-3","article-title":"Multivalent cytomegalovirus glycoprotein b nucleoside modified mrna vaccines did not demonstrate a greater antibody breadth","volume":"9","author":"Wang","year":"2024","journal-title":"NPJ Vaccines"},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0650","doi-asserted-by":"crossref","first-page":"e668","DOI":"10.1093\/infdis\/jiae114","article-title":"Safety and immunogenicity of a messenger rna-based cytomegalovirus vaccine in healthy adults: results from a phase 1, randomized, clinical trial","volume":"230","author":"Fierro","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0655","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01603-23","article-title":"Characterization of humoral and cellular immunologic responses to an mrna-based human cytomegalovirus vaccine from a phase 1 trial of healthy adults","volume":"98","author":"Wu","year":"2024","journal-title":"J. Virol."},{"issue":"Supplement_2","key":"10.1016\/j.ijbiomac.2025.146204_bb0660","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad500.2475","article-title":"2892. Safety and immunogenicity of mrna-1647, an mrna-based cytomegalovirus vaccine in healthy adults: Results of a phase 2, randomized, observer-blind, placebo-controlled, dose-finding trial","volume":"10","author":"Panther","year":"2023","journal-title":"Open Forum Infect. Dis."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0665","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/infdis\/jiad593","article-title":"Human cytomegalovirus mrna-1647 vaccine candidate elicits potent and broad neutralization and higher antibody-dependent cellular cytotoxicity responses than the gb\/mf59 vaccine","volume":"230","author":"Hu","year":"2024","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.ijbiomac.2025.146204_bb0670","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.0020109","article-title":"High epitope expression levels increase competition between t cells","volume":"2","author":"Scherer","year":"2006","journal-title":"PLoS Comput. Biol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0675","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1016\/j.vaccine.2018.01.029","article-title":"Multi-antigenic human cytomegalovirus mrna vaccines that elicit potent humoral and cell-mediated immunity","volume":"36","author":"John","year":"2018","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0680","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1038\/mt.2014.133","article-title":"A cationic nanoemulsion for the delivery of next-generation rna vaccines","volume":"22","author":"Brito","year":"2014","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0685","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12010138","article-title":"Self-amplifying RNA vaccine candidates: alternative platforms for mRNA vaccine development","volume":"12","author":"Schmidt","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","article-title":"Epstein\u2013barr virus and cancer","volume":"14","author":"Farrell","year":"2019","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0695","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1093\/gbe\/evu054","article-title":"Genome-wide analysis of wild-type epstein-barr virus genomes derived from healthy individuals of the 1,000 genomes project","volume":"6","author":"Santpere","year":"2014","journal-title":"Genome Biol. Evol."},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0700","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","article-title":"Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an epstein-barr virus vaccine in healthy young adults","volume":"196","author":"Sokal","year":"2007","journal-title":"J. Infect. Dis."},{"issue":"20","key":"10.1016\/j.ijbiomac.2025.146204_bb0705","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192013054","article-title":"Mrna-based vaccine designing against epstein-barr virus to induce an immune response using immunoinformatic and molecular modelling approaches","volume":"19","author":"Althurwi","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"14","key":"10.1016\/j.ijbiomac.2025.146204_bb0710","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1158\/1078-0432.CCR-15-2299","article-title":"High levels of antibody that neutralize b-cell infection of epstein-barr virus and that bind ebv gp350 are associated with a lower risk of nasopharyngeal carcinoma","volume":"22","author":"Coghill","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"5","key":"10.1016\/j.ijbiomac.2025.146204_bb0715","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","article-title":"Immunization with components of the viral fusion apparatus elicits antibodies that neutralize epstein-barr virus in b cells and epithelial cells","volume":"50","author":"Bu","year":"2019","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0720","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics17010052","article-title":"Specific immune responses and oncolytic effects induced by EBV LMP2A-armed modified Ankara-vaccinia virus vectored vaccines in nasopharyngeal cancer","volume":"17","author":"Sun","year":"2025","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0725","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s12951-023-02069-w","article-title":"Lmp2-mrna lipid nanoparticle sensitizes ebv-related tumors to anti-pd-1 therapy by reversing t cell exhaustion","volume":"21","author":"Xiang","year":"2023","journal-title":"J. Nanobiotechnol."},{"issue":"35","key":"10.1016\/j.ijbiomac.2025.146204_bb0730","article-title":"Mrna-based vaccines targeting the t-cell epitope-rich domain of epstein barr virus latent proteins elicit robust anti-tumor immunity in mice","volume":"10","author":"Zhao","year":"2023","journal-title":"Adv. Sci. (Weinh)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0735","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s40203-024-00244-x","article-title":"Mrna vaccine design for epstein-barr virus: An immunoinformatic approach","volume":"12","author":"Oladipo","year":"2024","journal-title":"In Silico Pharmacol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2025.146204_bb0740","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1038\/s41467-023-39770-1","article-title":"Lymph node targeted multi-epitope subunit vaccine promotes effective immunity to ebv in hla-expressing mice","volume":"14","author":"Dasari","year":"2023","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0745","article-title":"Epstein-barr virus mrna vaccine synergizes with nk cells to enhance nasopharyngeal carcinoma eradication in humanized mice","volume":"33","author":"Huang","year":"2025","journal-title":"Mol. Ther. Oncol."},{"issue":"13","key":"10.1016\/j.ijbiomac.2025.146204_bb0750","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23137203","article-title":"Human gammaherpesvirus 8 oncogenes associated with Kaposi\u2019s sarcoma","volume":"23","author":"Lopes","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0755","doi-asserted-by":"crossref","DOI":"10.3390\/v14030541","article-title":"Antibodies targeting KSHV GH\/GL reveal distinct neutralization mechanisms","volume":"14","author":"Fricke","year":"2022","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0760","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02913-24","article-title":"Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the in vivo immunogenicity and efficacy of KSHV vaccine candidates","volume":"15","author":"Yang","year":"2024","journal-title":"MBio"},{"issue":"12","key":"10.1016\/j.ijbiomac.2025.146204_bb0765","doi-asserted-by":"crossref","first-page":"6389","DOI":"10.1128\/JVI.78.12.6389-6398.2004","article-title":"Kaposi\u2019s sarcoma-associated herpesvirus glycoprotein k8.1 is dispensable for virus entry","volume":"78","author":"Luna","year":"2004","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2025.146204_bb0770","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3390\/v12030256","article-title":"The kaposi's sarcoma-associated herpesvirus (kshv) gh\/gl complex is the predominant neutralizing antigenic determinant in kshv-infected individuals","volume":"12","author":"Mortazavi","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0775","doi-asserted-by":"crossref","first-page":"439","DOI":"10.18632\/oncotarget.28600","volume":"15","author":"Barasa","year":"2024","journal-title":"Oncotarget"},{"issue":"9","key":"10.1016\/j.ijbiomac.2025.146204_bb0780","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1172\/JCI179483","article-title":"Therapeutic vaccines for herpesviruses","volume":"134","author":"Cohen","year":"2024","journal-title":"J. Clin. Invest."},{"issue":"4","key":"10.1016\/j.ijbiomac.2025.146204_bb0785","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1007\/s11427-022-2230-4","article-title":"Current progress in the development of prophylactic and therapeutic vaccines","volume":"66","author":"Li","year":"2023","journal-title":"Sci. China Life Sci."},{"issue":"11","key":"10.1016\/j.ijbiomac.2025.146204_bb0790","article-title":"Prophylactic and therapeutic ebv vaccines: major scientific obstacles, historical progress, and future direction","volume":"9","author":"Cai","year":"2021","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.ijbiomac.2025.146204_bb0795","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41579-020-00448-w","article-title":"The structural basis of herpesvirus entry","volume":"19","author":"Connolly","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0800","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1445209","article-title":"Multivalent mva-vectored vaccine elicits ebv neutralizing antibodies in rhesus macaques that reduce ebv infection in humanized mice","volume":"15","author":"Escalante","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0805","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.actbio.2024.12.022","article-title":"Fluorinated polyethyleneimine vectors with serum resistance and adjuvant effect to deliver lmp2 mrna vaccine for nasopharyngeal carcinoma therapy","volume":"192","author":"Yang","year":"2025","journal-title":"Acta Biomater."},{"issue":"6","key":"10.1016\/j.ijbiomac.2025.146204_bb0810","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10719-022-10083-7","article-title":"Envelope glycoprotein based multi-epitope vaccine against a co-infection of human herpesvirus 5 and human herpesvirus 6 using in silico strategies","volume":"39","author":"Gandhamaneni","year":"2022","journal-title":"Glycoconj. J."},{"issue":"17","key":"10.1016\/j.ijbiomac.2025.146204_bb0815","doi-asserted-by":"crossref","first-page":"6585","DOI":"10.1080\/07391102.2020.1803969","article-title":"Designing novel epitope-based polyvalent vaccines against herpes simplex virus-1 and 2 exploiting the immunoinformatics approach","volume":"39","author":"Sarkar","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2025.146204_bb0820","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1586271","article-title":"Reverse vaccinology-based design of multivalent multiepitope mRNA vaccines targeting key viral proteins of herpes simplex virus type-2","volume":"16","author":"Suneesh","year":"2025","journal-title":"Front. Immunol."}],"updated-by":[{"DOI":"10.1016\/j.ijbiomac.2025.147610","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000}}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025067613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813025067613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T14:33:27Z","timestamp":1763044407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813025067613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":164,"alternative-id":["S0141813025067613"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146204","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mRNA vaccines: Emerging opportunities for herpesvirus prevention and therapeutic intervention","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2025.146204","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"146204"}}